Literature DB >> 33575300

Tenofovir vs. entecavir in reducing hepatocellular carcinoma risk in patients with chronic HBV infection?-Still an unsolved question.

Hyun-Seok Kim1, Hashem B El-Serag1,2.   

Abstract

Entities:  

Year:  2021        PMID： 33575300      PMCID： PMC7867738          DOI： 10.21037/hbsn-2020-3

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  17 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

2.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.

Authors:  Linda E Lévesque; James A Hanley; Abbas Kezouh; Samy Suissa
Journal:  BMJ       Date:  2010-03-12

3.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

4.  Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.

Authors:  Jonggi Choi; Hyo Jeong Kim; Jayoun Lee; Songhee Cho; Min Jung Ko; Young-Suk Lim
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

5.  Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.

Authors:  Terry Cheuk-Fung Yip; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan; Yee-Kit Tse; Grace Chung-Yan Lui; Grace Lai-Hung Wong
Journal:  Gastroenterology       Date:  2019-09-28       Impact factor: 22.682

6.  A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.

Authors:  Seung Up Kim; Yeon Seok Seo; Han Ah Lee; Mi Na Kim; Yu Rim Lee; Hye Won Lee; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Seong Gyu Hwang; Kyu Sung Rim; Soon Ho Um; Won Young Tak; Young Oh Kweon; Beom Kyung Kim; Soo Young Park
Journal:  J Hepatol       Date:  2019-04-06       Impact factor: 25.083

7.  HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.

Authors:  Terry Cheuk-Fung Yip; Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Yee-Kit Tse; Kelvin Long-Yan Lam; Grace Chung-Yan Lui; Vincent Wai-Sun Wong
Journal:  J Hepatol       Date:  2018-10-25       Impact factor: 25.083

8.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

Authors:  Peter C Austin
Journal:  Multivariate Behav Res       Date:  2011-06-08       Impact factor: 5.923

9.  Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.

Authors:  Sung Won Lee; Jung Hyun Kwon; Hae Lim Lee; Sun Hong Yoo; Hee Chul Nam; Pil Soo Sung; Soon Woo Nam; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Nam Ik Han; Jeong Won Jang
Journal:  Gut       Date:  2019-10-31       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.